Mithra Pharma : Announces the Leave of its CFO

MITHRA ANNOUNCES THE LEAVE OF ITS CFO PRESS RELEASE Mithra Pharmaceuticals announces today that the Company and its CFO Steven Peters end their contractual relationship in common agreement. Liège, Belgium 31 October 2016 - Mithra Pharmaceuticals, a company dedicated to Women's Health, announces that it has come to a common agreement to end the contractual relationship with its CFO Steven Peters as of today. Mr Peters will remain partly on board during a transition period of 6 months in which he will support and assist the company in its search for a replacer. During this period he will be no longer part of the Executive Committee and his responsabilities will be assumed by the CEO. François Fornieri, CEO Mithra Pharmaceuticals: "Steven Peters has played an important role in recent years at Mithra and we are thankfull for his support in the IPO process in 2015. We are whishing him the best of luck in his further carreer. In the meantime we have initiated the search for a new CFO and we are looking forward to meet and engage soon with a new CFO." Pictures For pictures of François Fornieri, please click here on the following link: For more information, please contact: Press Julie Dessart Chief Communication Officer +32 4 349 28 22 +32 475 86 41 75 [email protected] Investor Relations François Fornieri, CEO +32 4 349 28 22 [email protected] About MithraMithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers. Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: Important information The contents of this announcement include statements that are, or may be deemed to be, "forward- looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. To subscribe to Mithra's newsletter, visit Mithra Pharmaceuticals SA published this content on 31 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 October 2016 08:02:13 UTC.

Source :

Related Posts